GlassScriptPhysician profile
James Gillespie
NPI 1376078808
$8,133.52
in general payments reported to CMS, 2019-2025
24 companies · $1,361 in 2025
The $1,361 reported for 2025 was more than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,500 · 2022: $98.50 · 2023: $3,092 · 2024: $1,082 · 2025: $1,361.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,889 · Travel and Lodging: $1,604 · Education: $42.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,888.80 |
| Travel and Lodging | $1,604.22 |
| Education | $42.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $3,679.73 | 2022-2025 | Wavewriter Alpha Prime 16, Infinion 16, Clinical Trial Product |
| Medtronic, INC. | $2,564.02 | 2021-2023 | Kyphon Express II Kyphopak Tray |
| Forte Bio-Pharma LLC | $361.14 | 2023-2025 | Prolate, Nalocet, Tanlor |
| Collegium Pharmaceutical, INC. | $245.51 | 2023-2025 | Xtampza |
| Spr Therapeutics, INC | $166.72 | 2024-2025 | Sprint Pns System |
| Scilex Pharmaceuticals INC. | $153.23 | 2024-2025 | |
| Saluda Medical Americas, INC. | $135.65 | 2023-2025 | Evoke, Evoke Scs |
| Alexion Pharmaceuticals, INC. | $125.61 | 2022-2024 | Soliris, Ultomiris |
| Abbott Laboratories | $120.08 | 2025 | Proclaim |
| Spinal Simplicity, LLC | $110.79 | 2025 | Ha Minuteman G3-R |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $106.40 | 2024-2025 | Relistor |
| Almatica Pharma LLC | $45.83 | 2022-2023 | Gralise |
| Indivior INC. | $43.41 | 2025 | Sublocade |
| Hikma Pharmaceuticals USA | $42.00 | 2023 | Kloxxado |
| Pacira Pharmaceuticals Incorporated | $36.45 | 2024 | Zilretta, Iovera |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ibsa Pharma INC. | $30.73 | 2023-2024 | Tirosint, Tirosint, Flector |
| Azurity Pharmaceuticals, INC. | $30.10 | 2024 | Horizant |
| Braeburn INC. | $26.55 | 2025 | Brixadi |
| Vertos Medical, INC. | $24.79 | 2024 | Mild Device Kit |
| Si-Bone, INC. | $23.24 | 2024 | |
| Mml US, INC. | $17.50 | 2023 | Reactiv8 |
| Trevena, INC. | $16.46 | 2023 | Olinvyk |
| Abbvie INC. | $13.80 | 2025 | |
| Idorsia Pharmaceuticals US INC | $13.78 | 2024 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Gillespie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.